A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs Dacarbazine; Olaparib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 20 May 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 20 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2008 Planned end date changed from 1 Jun 2009 to 1 Oct 2008 as reported by ClinicalTrials.gov.